TELA
Income statement / Annual
Last year (2025), TELA Bio Inc's total revenue was $80.28 M,
an increase of 15.84% from the previous year.
In 2025, TELA Bio Inc's net income was -$38.83 M.
See TELA Bio Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$80.28 M |
$69.30 M |
$58.45 M |
$41.42 M |
$29.46 M |
$18.21 M |
$15.45 M |
$8.27 M |
$4.25 M |
| Cost of Revenue |
$25.93 M
|
$22.81 M
|
$18.34 M
|
$14.37 M
|
$10.65 M
|
$6.98 M
|
$6.17 M
|
$5.33 M
|
$1.71 M
|
| Gross Profit |
$54.34 M
|
$46.49 M
|
$40.11 M
|
$27.04 M
|
$18.81 M
|
$11.23 M
|
$9.27 M
|
$2.94 M
|
$2.53 M
|
| Gross Profit Ratio |
0.68
|
0.67
|
0.69
|
0.65
|
0.64
|
0.62
|
0.6
|
0.36
|
0.6
|
| Research and Development Expenses |
$9.22 M
|
$8.81 M
|
$9.62 M
|
$8.94 M
|
$6.74 M
|
$4.26 M
|
$4.15 M
|
$4.34 M
|
$5.79 M
|
| General & Administrative Expenses |
$15.69 M
|
$14.72 M
|
$14.89 M
|
$13.86 M
|
$12.46 M
|
$10.14 M
|
$6.22 M
|
$4.90 M
|
$4.96 M
|
| Selling & Marketing Expenses |
$63.18 M
|
$64.65 M
|
$59.68 M
|
$43.25 M
|
$29.06 M
|
$22.11 M
|
$18.06 M
|
$13.65 M
|
$8.71 M
|
| Selling, General & Administrative Expenses |
$78.88 M
|
$79.37 M
|
$74.57 M
|
$57.11 M
|
$41.52 M
|
$32.25 M
|
$24.28 M
|
$18.55 M
|
$13.67 M
|
| Other Expenses |
$0.00
|
-$7.58 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$70.00 K
|
$94.00 K
|
| Operating Expenses |
$88.10 M
|
$80.60 M
|
$84.19 M
|
$66.05 M
|
$48.26 M
|
$36.51 M
|
$28.43 M
|
$22.88 M
|
$19.46 M
|
| Cost And Expenses |
$114.03 M
|
$103.42 M
|
$102.53 M
|
$80.43 M
|
$58.91 M
|
$43.49 M
|
$34.61 M
|
$28.22 M
|
$21.17 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$5.25 M
|
$5.29 M
|
$5.22 M
|
$4.05 M
|
$3.60 M
|
$3.56 M
|
$3.61 M
|
$1.80 M
|
$4.56 M
|
| Depreciation & Amortization |
$0.00
|
$1.01 M
|
$808.00 K
|
$1.19 M
|
$535.00 K
|
$525.00 K
|
$582.00 K
|
$1.25 M
|
$761.00 K
|
| EBITDA |
-$33.76 M |
-$31.68 M |
-$40.63 M |
-$39.06 M |
-$29.14 M |
-$24.71 M |
-$18.23 M |
-$18.04 M |
-$16.02 M |
| EBITDA Ratio |
-0.42
|
-0.46
|
-0.7
|
-0.94
|
-0.99
|
-1.36
|
-1.18
|
-2.18
|
-3.77
|
| Operating Income Ratio |
-0.42
|
-0.49
|
-0.75
|
-0.94
|
-1
|
-1.39
|
-1.24
|
-2.15
|
-3.99
|
| Total Other Income/Expenses Net |
-$4.85 M
|
-$3.87 M
|
-$2.59 M
|
-$5.29 M
|
-$3.83 M
|
-$3.52 M
|
-$3.26 M
|
-$3.31 M
|
-$4.41 M
|
| Income Before Tax |
-$38.60 M
|
-$37.99 M
|
-$46.66 M
|
-$44.30 M
|
-$33.28 M
|
-$28.79 M
|
-$22.43 M
|
-$21.09 M
|
-$21.33 M
|
| Income Before Tax Ratio |
-0.48
|
-0.55
|
-0.8
|
-1.07
|
-1.13
|
-1.58
|
-1.45
|
-2.55
|
-5.03
|
| Income Tax Expense |
$230.00 K
|
-$144.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$38.83 M
|
-$37.84 M
|
-$46.66 M
|
-$44.30 M
|
-$33.28 M
|
-$28.79 M
|
-$22.43 M
|
-$21.09 M
|
-$21.33 M
|
| Net Income Ratio |
-0.48
|
-0.55
|
-0.8
|
-1.07
|
-1.13
|
-1.58
|
-1.45
|
-2.55
|
-5.03
|
| EPS |
-0.83 |
-1.33 |
-2.04 |
-2.73 |
-2.3 |
-2.23 |
-2.26 |
-3.25 |
-3.29 |
| EPS Diluted |
-0.83 |
-1.33 |
-2.04 |
-2.73 |
-2.3 |
-2.23 |
-2.26 |
-3.25 |
-3.29 |
| Weighted Average Shares Out |
$46.95 M
|
$28.53 M
|
$22.87 M
|
$16.27 M
|
$14.47 M
|
$12.93 M
|
$11.41 M
|
$6.49 M
|
$6.49 M
|
| Weighted Average Shares Out Diluted |
$46.95 M
|
$28.53 M
|
$22.87 M
|
$16.27 M
|
$14.47 M
|
$12.93 M
|
$11.41 M
|
$6.49 M
|
$6.49 M
|
| Link |
|
|
|
|
|
|
|
|
|
